KENNESAW, Ga., Jan. 10, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has received the certification for the Company's proprietary CollaFix™ Surgical Mesh CD. This certification of CollaFix™ Surgical Mesh CD, which is a Class III product in Europe, was issued by the Company's notified body, AMTAC Certification Services, Limited, based in the United Kingdom.
This certification is the first for the Company's CollaFix™ platform technology.
Parker H. "Pete" Petit, Chairman and CEO commented, "We are very pleased to receive our first regulatory certification for our unique CollaFix™ technology. Our collagen fibers, that are the size of human hair, are fabricated in continuous lengths and have similar strength and stiffness to human tendons. The fibers are bio-compatible and resorbable. We expect this certification to be the first of many in a line of products using our CollaFix™ technologies to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair."
CollaFix™ Surgical Mesh CD has not been cleared for use in the United States.
About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix®, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane,
|SOURCE MiMedx Group, Inc.|
Copyright©2010 PR Newswire.
All rights reserved